PL407949A1 - Kompozycja lipidowa służąca do wytworzenia kierowanego za pomocą przeciwciał liposomowego nośnika leków genetycznych oraz jej zastosowanie - Google Patents

Kompozycja lipidowa służąca do wytworzenia kierowanego za pomocą przeciwciał liposomowego nośnika leków genetycznych oraz jej zastosowanie

Info

Publication number
PL407949A1
PL407949A1 PL407949A PL40794914A PL407949A1 PL 407949 A1 PL407949 A1 PL 407949A1 PL 407949 A PL407949 A PL 407949A PL 40794914 A PL40794914 A PL 40794914A PL 407949 A1 PL407949 A1 PL 407949A1
Authority
PL
Poland
Prior art keywords
weight
application
lipid composition
antibodies
creation
Prior art date
Application number
PL407949A
Other languages
English (en)
Other versions
PL233741B1 (pl
Inventor
Monika Toporkiewicz
Justyna Meissner
Kazimierz Kuliczkowski
Aleksander Sikorski
Original Assignee
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością filed Critical Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL407949A priority Critical patent/PL233741B1/pl
Priority to PCT/PL2015/050011 priority patent/WO2015160271A1/en
Publication of PL407949A1 publication Critical patent/PL407949A1/pl
Publication of PL233741B1 publication Critical patent/PL233741B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem wynalazku jest kompozycja lipidowa służąca do wytworzenia kierowanego za pomocą przeciwciał liposomowego nośnika leków genetycznych w postaci asODN, siRNA, miRNA, rybozymowego RNA oraz DNazymu, charakteryzująca się tym, że zawiera od 35,2% do 45,7% wagowych fosfatydylocholiny (PC), od 12,3% do 19,1% wagowych dioleilofosfatydyloetanolaminy (DOPE), od 4,9% do 6,4% wagowych 3ß-N-dimetyloetanokarbamoilocholesterolu (DC-CHOL), od 10,7% do 16,6% wagowych DSPE-PEG, od 4,6% do 6,2% wagowych maleimidowej pochodnej DSPE-PEG (DSPE-PEG-Mal) oraz od 10,6% do 25,7% wagowych soli trimetyloaminowej 1,2-dioleilopropanu (DOTAP) oraz jej zastosowanie.
PL407949A 2014-04-18 2014-04-18 Kompozycja lipidowa sluzaca do wytworzenia kierowanego za pomoca przeciwcial liposomowego nosnika lekow genetycznych oraz jej zastosowanie PL233741B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL407949A PL233741B1 (pl) 2014-04-18 2014-04-18 Kompozycja lipidowa sluzaca do wytworzenia kierowanego za pomoca przeciwcial liposomowego nosnika lekow genetycznych oraz jej zastosowanie
PCT/PL2015/050011 WO2015160271A1 (en) 2014-04-18 2015-04-18 Lipid composition used for construction of liposomal genetic drug carrier targeted with antibodies, and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL407949A PL233741B1 (pl) 2014-04-18 2014-04-18 Kompozycja lipidowa sluzaca do wytworzenia kierowanego za pomoca przeciwcial liposomowego nosnika lekow genetycznych oraz jej zastosowanie

Publications (2)

Publication Number Publication Date
PL407949A1 true PL407949A1 (pl) 2015-10-26
PL233741B1 PL233741B1 (pl) 2019-11-29

Family

ID=54324351

Family Applications (1)

Application Number Title Priority Date Filing Date
PL407949A PL233741B1 (pl) 2014-04-18 2014-04-18 Kompozycja lipidowa sluzaca do wytworzenia kierowanego za pomoca przeciwcial liposomowego nosnika lekow genetycznych oraz jej zastosowanie

Country Status (2)

Country Link
PL (1) PL233741B1 (pl)
WO (1) WO2015160271A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR132018074482E2 (pt) * 2018-11-27 2020-06-02 Universidade Estadual De Campinas - Unicamp Processo microfluídico de obtenção de lipossomas stealth catiônicos
CN111904934B (zh) * 2020-09-21 2022-02-25 中国医学科学院医药生物技术研究所 miRNA185抑制剂的脂质体及其制法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100794449B1 (ko) 2007-03-29 2008-01-16 고려대학교 산학협력단 핵산 전달용 양이온성 인지질 나노입자 조성물
PL208054B1 (pl) 2007-09-06 2011-03-31 Akademia Medyczna Im Piastow Śląskich We Wrocławiu Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie
CA2710983A1 (en) 2007-12-27 2009-10-01 The Ohio State University Research Foundation Lipid nanoparticle compositions and methods of making and using the same
IT1405683B1 (it) * 2010-10-18 2014-01-24 Istituto Giannina Gaslini Vettori lipidici veicolanti silenziatori genici

Also Published As

Publication number Publication date
WO2015160271A1 (en) 2015-10-22
PL233741B1 (pl) 2019-11-29

Similar Documents

Publication Publication Date Title
IL281615A (en) Systems and methods for manufacturing lipid nanoparticles and liposomes
AU2019333042B2 (en) Improved process of preparing mRNA-loaded lipid nanoparticles
MX2017003794A (es) Formulaciones estables de lipidos y liposomas.
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
GB2600859B (en) Improved lipid nanoparticles for delivery of nucleic acids
IL266501A (en) An improved ice-based lipid nanoparticle formulation for mRNA delivery
SG11202108100PA (en) Methods of preparing lipid nanoparticles
IL288020A (en) An improved process for the preparation of RNA-loaded lipid nanoparticles
EP4036079A3 (en) Compounds and compositions for intracellular delivery of agents
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
MX393573B (es) Composiciones de acido ribonucleico mensajero del regulador transmembrana de fibrosis quistica y metodos y usos relacionados
EP3129008A4 (en) Liposomes that form drug nanocrystals after freeze-thaw
MX390195B (es) Vectores para uso en un sistema de coexpresion inducible.
FR3008979B1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CL2017003067A1 (es) Piridinas sustituidas y método de uso
GB2538683A8 (en) Irinotecan hydrochloride composite phospholipid composition preparation method and use thereof
EP3252152A4 (en) Method for mass producing natural killer cell and use of natural killer cell obtained by the method as anti-cancer agent
PE20211249A1 (es) PRODUCTO DE FARMACO DE siARN PARA INHIBIR LA EXPRESION DE ALAS1 Y COMPOSICION QUE LO COMPRENDE
EP3147277A4 (en) LIPID MEMBRANE STRUCTURE FOR siRNA INTRACELLULAR DELIVERY
CY1122080T1 (el) 7-(μορφολινυλ)-2-(n-πιπεραζινυλ) μεθυλοθειαινο [2,3-c]πυριδινης ως αντικαρκινικα φαρμακα
EP3442544A4 (en) IMPROVED GENE RELEASE PROCEDURES
IL261516A (en) Methods and compositions for increased double stranded rna production
PL383287A1 (pl) Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie
PL407949A1 (pl) Kompozycja lipidowa służąca do wytworzenia kierowanego za pomocą przeciwciał liposomowego nośnika leków genetycznych oraz jej zastosowanie
EA201890271A1 (ru) Составы для повышения эффективности гидрофобных лекарственных средств